@article{114bd0fc8fa74d8294d0db785e513e56,
title = "The TEAMMATE Trial: Study Design and Rationale of the First Pediatric Heart Transplant Randomized Clinical Trial.",
author = "C. Almond and L.A. Sleeper and J.W. Rossano and E. Pahl and A.K. Lal and C.D. Castleberry and J. Lee and S. Hollander and G. Klein and L.M. Barkoff and M. Fenton and M. Bock and K.P. Daly and Bock, \{Matthew J.\}",
note = "Currently there are no-FDA approved immunosuppressants specific to pediatric heart transplantation (HT). In recent years, everolimus (EVL) has emerged as an alternative to tacrolimus (TAC) as a primary immunosuppressant to prevent rejection that may also prevent kidney and coronary disease. However, the two regimens have never been evaluated systematically.",
year = "2020",
month = mar,
day = "30",
doi = "10.1016/J.HEALUN.2020.01.825",
language = "American English",
volume = "39",
journal = "Journal of Heart and Lung Transplantation",
}